Drugs giant AstraZeneca has admitted that the formulation patent protecting its Seroquel XR product was deemed invalid by the High Court in the UK.
The patent was challenged by Accord Healthcare, Intas Pharmaceuticals, Hexal AG and Sandoz, Teva UK, and Teva Pharmaceutical Industries.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
AstraZeneca said it is "disappointed" with the court's decision and added that the company remains committed to defending its intellectual property protecting Seroquel XR.
Shares were down 0.26% to 2,844.00p.
NR
-
Would you delay retirement to help your children through university?Parents are missing out on as much as £45,000 that could have gone into their pensions because they are using that money to pay their children’s way through university, according to new research
-
Family face £100k stamp duty bill after avoidance scheme crashes in court – the mistakes to avoidA couple faces a substantial stamp duty bill after trying to reduce the amount they owed
